Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia

Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia

Abstract CD19 chimeric antigen receptor (CAR)-T cells have been used to treat patients with refractory chronic lymphocytic leukemia (CLL). However, approximately 50% of patients do not respond to this therapy. To improve the clinical outcome of these patients, it is necessary to develop strategies w...

Full description

Bibliographic Details
Main Authors: Guoling Wang, Xiaolei Sun, Shiyu Zuo, Chuo Li, Qing Niu, Yonghui Xia, Yuan Meng, Min Liu, Zihao Fang, Xi Yang, Yanyu Jiang, Sheng Wang, Haidong Cui, Huifang Huang, Erlie Jiang, Dongming Zhou, Qi Deng, Jing Pan, Xiaoming Feng
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Journal of Hematology & Oncology
Subjects:
Chronic lymphocytic leukemia
CD32b
Chimeric antigen receptor
Antigen site density
Online Access:https://doi.org/10.1186/s13045-021-01160-9

Internet

https://doi.org/10.1186/s13045-021-01160-9

Similar Items